Skip to content
  1. Specialized Offerings Thrive: Making robots is hard and costs a lot of money. With funding harder to come by, many companies who do one thing and do it right will benefit from proven revenue streams. Look for growth from companies making robots for the difficult, dirty, and dangerous jobs like energy and utilities inspection, as well as those tackling issues arising from climate change, such as irrigation monitoring and optimization.
  2. Autonomous Vehicle (AV) Companies Face a Difficult Balancing Act: Last year’s high-profile safety incidents will continue to be a challenge for AV, leading to delays and more human-in-the-loop oversight. But these measures may increase costs and thereby make it more difficult to compete with today’s less expensive alternatives, particularly when it comes to rideshares. Both safety and profitability are critical to success in this industry and AV companies will be forced to walk a tightrope between the two as pressures mount to prove the viability of this tech and associated business models.
  3. Drone Industry Consolidation Ramps Up: 2023 was a tough year in the drone world. The abrupt exits of several well-known players sent shockwaves through the industry while many had to resort to product line consolidations and layoffs to stay afloat. The headwinds will likely continue through 2024, but well-funded companies and those with profitable market niches will weather the storm and emerge stronger via low-cost acquisitions and less competition for investment dollars and talent. Regulatory progress – especially in Beyond Visual Line of Sight (BVLOS) and one-to-many operations – will continue to dictate scalability in many respects.
  4. Robotic-Assistance Improves the Surgical Outcome: Robotic-assisted surgeries will continue to become more popular. While the robots are unlikely to fully replace human surgeons in the near future, surgical robotic systems provide surgeons with tools, such as assistance in pre-operative planning, enhanced navigation and visualization systems, and more precise tool handling, that will enable them to perform more complex surgical procedures and improve their outcome.
  5. IP will Continue to Play a Critical Role: Many early stage companies found 2023 to be a difficult year to raise funds. As they wait for markets to open up, early stage companies should invest in building strong, strategic patent portfolios to protect their technologies. A strong IP position can help robotics companies differentiate themselves from competition and attract investors.
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Todd Basile Todd Basile

Todd helps technology companies and investors protect and commercialize their innovations across a wide range of industries including software, robotics, autonomous vehicles, medical devices, and aerospace.

His practice offers a full suite of IP-related legal services including:

  • Patents – Developing portfolios tailored to

Todd helps technology companies and investors protect and commercialize their innovations across a wide range of industries including software, robotics, autonomous vehicles, medical devices, and aerospace.

His practice offers a full suite of IP-related legal services including:

  • Patents – Developing portfolios tailored to your company’s particular goals such as attracting investment, protecting market share, or having bargaining chips in disputes with competitors
  • M&A and Investment – Helping investors understand what they are buying and mitigating the associated risks; helping sellers position their technology assets to maximize company valuation and attract (and close) funding opportunities
  • Tech Transactions – Negotiating partnerships to grow the company, while protecting your IP and technology and minimizing business disruption should future problems arise
  • Freedom to Operate – Guiding product design to avoid infringing third-party patent rights
  • Software Development & Licensing – Navigating the numerous software-related legal issues such as ownership, subscription licensing (SaaS), control, data privacy and security, source code escrow, and open source software (OSS) risks

Prior to becoming an attorney, Todd was an engineer at Bell Helicopter where he designed cutting-edge aerospace technologies and software. Todd also helped develop electromechanical control systems for military drones at Smiths Aerospace during his undergraduate studies at Georgia Tech, and clerked at St. Jude Medical’s Neuromodulation Division during law school.

Photo of David J. Dykeman David J. Dykeman

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.

David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.

An author of over 50 articles and a speaker at over 45 conferences on intellectual property law, David is the founding co-chair of the ABA’s Medical Devices Committee. He was honored as one of Boston’s “40 Under 40” innovative business leaders by the Boston Business Journal and was named to the “40 Medtech Innovators Under 40” list by Medical Device & Diagnostic Industry (MD+DI) Magazine. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an “IP Star” by Managing IP magazine, a “Life Science Star” by LMG Life Sciences, and one of the World’s Leading IP Strategists in the IAM 300.

Photo of Roman Fayerberg Roman Fayerberg

Roman Fayerberg is a registered patent attorney with broad experience helping clients to strategically protect and leverage their innovations globally. Roman works with clients to develop and manage worldwide patent portfolios and counsels clients in regard to freedom to operate, patent landscape, and…

Roman Fayerberg is a registered patent attorney with broad experience helping clients to strategically protect and leverage their innovations globally. Roman works with clients to develop and manage worldwide patent portfolios and counsels clients in regard to freedom to operate, patent landscape, and patent infringement and validity matters. He also conducts and defends patent due diligence investigations in connection with venture capital investments, mergers and acquisitions, and licensing opportunities.

Roman has represented clients ranging from start-ups to global companies in a variety of technical areas, including medical devices, robotics, diagnostic and imaging systems, microfluidic devices, and biotechnology. He understands the legal goals of each of his clients and develops and executes patent strategies that meet such goals.